Sarclisa

(isatuximab)

Uses, side effects, dosage information & price range

Sanofi Winthrop Industrie

About this medicine

Sarclisa is indicated:  In combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. In combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. In combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant. In combination with bortezomib, lenalidomide, and dexamethasone, for the induction treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.

Common Substitutes & Alternatives

These medicines share the same salt composition or therapeutic category and can be used as substitutes under professional medical supervision.

PoherdyComposition: pertuzumabOrganon N.V.

Price on RequestView Details →

MekinistComposition: trametinibNovartis Europharm Limited

Price on RequestView Details →

VijoiceComposition: alpelisibNovartis Europharm Limited

Price on RequestView Details →

KisqaliComposition: ribociclibNovartis Europharm Limited

Price on RequestView Details →

TecartusComposition: brexucabtagene autoleucelKite Pharma EU B.V.

Price on RequestView Details →

Key Information

Salt / Composition

isatuximab